Boehringer Ingelheim registers Phase 1 bioequivalence trial for survodutide formulationsNov 16Trial updateBoehringer Ingelheim
Boehringer posts BI 1291583 results; registers obrixtamig rollover and four more trialsNov 12Weekly roundup, 7 itemsBoehringer IngelheimzongertinibUpdated
Boehringer trial pairs obrixtamig with Zai Lab's ZL-1310 in SCLC and neuroendocrine cancersNov 12Trial updateBoehringer IngelheimZai Lab (Shanghai) Co., Ltd.
Boehringer posts zongertinib hepatic PK results; adds NYU-led empagliflozin dialysis trial updateNov 6Weekly roundup, 4 itemsBoehringer IngelheimempagliflozinUpdated
Boehringer posts Phase III AIRWARD COPD trial for verducatib; also lists Phase I BI 3821001 studyOct 30Weekly roundup, 5 itemsBoehringer IngelheimzongertinibUpdated
MD Anderson registers Phase 1a/1b trial combining Jazz's zanidatamab with Boehringer's zongertinib iOct 28Trial updateBoehringer IngelheimJazz Pharmaceuticals
Boehringer Ingelheim posts Brightline-2 brigimadlin results; BI 4060107 trial recruitsOct 15Weekly roundup, 5 itemsBoehringer Ingelheimempagliflozin
Boehringer Ingelheim registers Phase Ib/II trial testing obrixtamig plus pumitamig in SCLCOct 13Trial updateBioNTech SEBoehringer Ingelheim
Boehringer Ingelheim registers five new trials, spanning oncology, obesity, and ILD screeningOct 2Weekly roundup, 7 itemsBoehringer IngelheimempagliflozinUpdated
Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig, pumitamig in SCLCSep 28Trial updateBioNTech SEBoehringer Ingelheim
Boehringer Ingelheim registers Phase 1 bioavailability study for BI 3034701Sep 23Trial updateBoehringer Ingelheim
AIMEDBIO registers Phase I trial of BI 4060107 with Boehringer Ingelheim as collaboratorSep 18Trial updateBoehringer Ingelheim
Boehringer Ingelheim registers Phase 3 VERANDA-IIM trial of nerandomilast in myositisAug 27Trial updateBoehringer Ingelheimnerandomilast
Boehringer adds survodutide bioequivalence trial alongside BI 3000202 transporter studyAug 19Weekly roundup, 2 itemsBoehringer Ingelheim
Boehringer adds cardiac safety trial for verducatib alongside survodutide diabetes studyAug 12Weekly roundup, 2 itemsBoehringer Ingelheim
Boehringer Ingelheim completes IPF/PPF antifibrotic survey; BI 3822971 trial still recruitingAug 4Weekly roundup, 2 itemsBoehringer Ingelheim
Boehringer Ingelheim posts completed bioequivalence trial of two pramipexole tablet formulationsJul 27Trial updateBoehringer Ingelheimpramipexole
Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig with Zai Lab's ZL-1310 in SCLCJul 16Trial updateBoehringer IngelheimZai Lab (Shanghai) Co., Ltd.
Boehringer Ingelheim registers Phase I mass balance trial for BI 3034701Jul 16Trial updateBoehringer Ingelheim
Boehringer Ingelheim's Phase I obesity drug BI 3034701 trial listed as active, not recruitingJul 9Trial updateBoehringer Ingelheim